Previous Article | Next Article 
Applied and Environmental Microbiology, September 2006, p. 6405-6410, Vol. 72, No. 9
0099-2240/06/$08.00+0 doi:10.1128/AEM.03011-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Isolation and Characterization of a New T-Even Bacteriophage, CEV1, and Determination of Its Potential To Reduce Escherichia coli O157:H7 Levels in Sheep
Raul R. Raya,1,2
Peter Varey,1
Rebecca A. Oot,1
Michael R. Dyen,1
Todd R. Callaway,3
Tom S. Edrington,3
Elizabeth M. Kutter,1 and
Andrew D. Brabban1*
The Evergreen State College, Olympia, Washington
98505,1
Cerela-Conicet, Tucumán,
Argentina,2
USDA Agricultural Station, College Station, Texas
778453
Received 21 December 2005/
Accepted 25 June 2006
 |
ABSTRACT
|
|---|
Bacteriophage CEV1 was isolated from sheep resistant to Escherichia coli
O157:H7 colonization. In vitro, CEV1 efficiently infected E.
coli O157:H7 grown both aerobically and anaerobically. In vivo,
sheep receiving a single oral dose of CEV1 showed a 2-log-unit
reduction in intestinal E. coli O157:H7 levels within 2 days
compared to levels in the
controls.
 |
INTRODUCTION
|
|---|
Escherichia coli O157:H7 is a highly virulent food-borne
pathogen with an infective dose of
100 cells in humans
(5,
25). Infections can be
severe; symptoms include hemorrhagic colitis, hemolytic-uremic
syndrome, thrombotic thrombocytopenic purpura, and even death
(23-25,
31). Although E.
coli O157:H7 infections can be linked to a variety of sources,
primary contamination is usually ruminant related; cattle and other
ruminants act as asymptomatic reservoirs
(2,
6,
7,
11,
12,
15,
17,
30). Despite extensive
intervention strategies, human E. coli O157:H7 infections
still occur (7,
9,
14). Thus, recent
research has focused on the development of preharvest interventions to
reduce the entry of the pathogen into the food chain. Bacteriophages
have been used successfully as antibacterial agents in both human and
veterinary medicine and are one potential preharvest E. coli
O157:H7 control strategy
(4,
8,
18,
20,
22,
28,
32-34,
39). In this study we
describe a new T4-like bacteriophage, CEV1, isolated from sheep
resistant to colonization by E. coli O157:H7, and we discuss
its potential to control this
pathogen.
 |
Isolation and characterization of bacteriophage CEV1.
|
|---|
Crossbred
ewes (n = 22) were orally inoculated with
109 CFU/sheep of novobiocin-resistant E.
coli O157:H7 (NCTC 12900). In the first 2 days following
inoculation, these sheep fecally shed
102 CFU/g
12900. By day 3, no viable 12900 was detected. Each sheep was
rechallenged with
1011 CFU 12900 and monitored,
with similar results. The sheep were then challenged with E.
coli O157:H7 EDL 933 (109 CFU/sheep). Again, fecal
shedding decreased rapidly, and by day 4, EDL933 levels
were below the detection limit. These results were unprecedented at our
facility, where both strains are routinely used in vivo (typically
104 CFU/g is shed fecally for
10 days).
Feces collected from these ewes tested positive for E. coli
O157:H7-infecting phage. By using our standard enrichment protocol, a
new bacteriophage, CEV1, was isolated
(10).
CEV1 was
active against 17/19 E. coli O157:H7 strains tested, 9 strains
from 4/5 phylogenetic groups of the E. coli reference (ECOR)
collection, lab strains B and K-12, and strains from serogroups O43,
O126, O153, O158, and Omulti (Table
1) (27). No representatives
from serogroups O15 and O50 were lysed by CEV1. Using a set of isogenic
E. coli K-12 mutant pairs, with one member of each pair mutant
for a specific outer membrane protein, it was found that CEV1 uses
ompA as its receptor (data not shown)
(16).
Electron
micrographs (Fig.
1A) showed that CEV1 has an icosahedral head, linked by a
connector to a contractile tail with fibers at the distal end. The CEV1
genome of
180 kb (Fig.
1B) is digested by EcoRV
and NdeI but not by EcoRI, BamHI, PstI, SalI, or HindIII, suggesting
that CEV1 DNA contains a modified base, probably 5-hydroxymethyl
cytosine (data not shown). Based on its morphology and the sequence of
a 788-nucleotide DNA fragment (GenBank accession no.
AY331985) internal to the major capsid protein
gp23 (Fig. 1C),
CEV1 is closely related to T4 (95% sequence similarity) (Fig.
1D)
(40).

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 1. Characterization
of phage CEV1. (A) Electron micrograph of bacteriophage CEV1.
Arrows indicate tail fibers. Dimensions: head, 100 nm by 85 nm;
contractile tail, 100 nm by 15 nm. (B) Pulsed-field gel
electrophoresis of phage DNA, as observed on an ethidium
bromide-stained low-melting-point agarose gel (1%, wt/vol)(0.5x TBE, consisting of 45 mM Tris-borate and 1 mM EDTA [pH
8]) run for 20 h at 6 V/cm and 14°C with a pulse
period of 45 to 90 s. Lanes 1 and 5, DNA ladder
(Bio-Rad); lane 2, T4 DNA (175 kb); lane 3, DNA ladder composed of
phage (Pseudomonas 2a
[290 kb], T4 [175 kb], CEV2 [120 kb], and Pseudomonas
2b [45 kb]) DNA; lane 4, CEV1 DNA. (C) Ethidium
bromide-stained agarose (1%, wt/vol) gel of DNA-PCR amplification
reactions using primers Cap8
(TGAAGTTACCTTCACCACGACCGG) and Mzia1
(TGTTATIGGTATGGTICGICGTGCTAT) for gp23
(40). First lane, 1-kb
DNA ladder (Invitrogen, CA); second lane, phage CEV1; third lane, phage
T4 (positive control); fourth lane, phage T5 (negative control). (D)
Unrooted phylogenetic tree constructed using the more variable internal
region (amino acids 115 to 302) of the gp23 head protein of a
number of T4-like phages, including T4 (Protein Data Bank
accession no. NP049787), T6 (Q38055), KC69
(AAF61696), Tu1a (AAF61691), SV14 (CAB01542), RB69 (AAF61699), RB49
(CAB01539), RB43 (AAF61698), and AR1 (Q9ZXI0); Enterobacter
cloacae phage 1 (AAF61700); Aeromonas salmonicida phages
44RR2.8t (44RR; AAF61693) and 65 (AAF61694); Aeromonas
hydrophila phage Aeh1 (AAF61695); Burkholderia cepacia
phage 42 (AAF61692); Vibrio natriegens phage nt-1 (AAF61697);
and Vibrio parahaemolyticus phages KVP20 (BAA25880) and KVP40
(BAA25567). Subgroups of phage types are indicated by shading: white,
schizo T-evens; light gray, pseudo T-evens; black,
T-evens.
|
|
 |
Infection experiments.
|
|---|
Both aerobic and
anaerobic CEV1 infections of 12900 were productive. Aerobic infections
of 12900 (optical density at 600 nm [OD600],
0.3)
were carried out in shake flasks containing tryptic soy broth (TSB) at
37°C with agitation. CEV1 displayed an eclipse period of 18
min, a latent period of 26 min, and a burst size of
150
PFU/cell in experiments at a low multiplicity of infection (MOI;
0.1) (data not shown). At an MOI of
5, >99%
of the phages adsorbed, the bacterial population was reduced 5 log
units, and progeny phages were observed within 20 min (upon treatment
with CHCl3, the burst size was
100 PFU/cell) (Fig.
2A). Limited and variable lysis inhibition was observed; lysis began between
30 to 120 min, depending on conditions and the MOI, and took 30 to 60
min to reach completion. Anaerobic infections of 12900 were
conducted using adaptations of the Hungate technique
(N2 headspace) in 126-ml butyl rubber-sealed serum bottles
containing TSB. Within 5 min, >97% of the phages adsorbed, and
by 20 min, levels of bacterial survivors fell 4 log units (Fig.
2B). Similarly efficient
anaerobic infections were observed in bovine rumen fluid and
colon-simulating media (data not shown)
(26).
 |
Animal studies.
|
|---|
Animal studies were
carried out humanely (Southern Plains Agricultural Research Center
Institutional Animal Care and Use Committee protocol 01-002). Prior to
experimental treatment, 39 crossbred ewes from one flock were screened
for O157:H7-infecting phages by using standard enrichment techniques;
19 tested negative (10).
The others all contained the same new O157:H7-infecting phage (termed
CEV2 and currently undergoing characterization). Sheep (n
= 8) that tested negative were inoculated (by oral gavage) with
1010 CFU of novobiocin/nalidixic acid-resistant
933; after 3 days, 4/8 sheep were treated with a single oral dose of
CEV1 (
1011 PFU). The animals were humanely
euthanized 2 days later; bacterial counts (by plating on MacConkey agar
containing 20 µg/ml novobiocin and 25 µg/ml nalidixic
acid) of ruminal, cecal, and rectal contents showed that 933 levels
were reduced 2 to 3 log units (P > 0.05) in the ceca
and rectums of CEV1-treated sheep compared to levels in controls (Fig.
3).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3. Use
of CEV1 as a preslaughter treatment to remove resident E.
coli O157:H7 from the intestines of ruminants (sheep). Control
sheep (white bars) received only E. coli O157:H7
orally on day zero, while experimental sheep (gray bars) orally
received E. coli O157:H7 on day zero and then CEV1 on
day 3. Data were collected postmortem from various parts of the
animals' digestive tracts 5 days after O157:H7 inoculation and 2 days
after phage treatment. Error bars, standard
deviations.
|
|
Over the years, bacteriophages have frequently been isolated from
the intestinal tracts of ruminants
(1,
19,
29). Swain et al. (1996)
studied bovine ruminal phage and concluded that phage help maintain
microbial diversity and balance
(37). Here we suggest
that phage also play a role in controlling the microbial ecology in the
colons of livestocka role that could be adapted as a
preharvest treatment to remove E. coli O157:H7 from sheep and
other ruminants. In this study, we found two sheep flocks from
different regions that harbored O157:H7-infecting phage (group 1 was
the CEV1 isolation flock, while group 2 was the CEV1 treatment test
flock [20/39 sheep harbored CEV2]). CEV1 was isolated from
sheep that cleared E. coli O157:H7 rapidly and were therefore
"resistant" to colonization. In view of the origin of
CEV1 and its demonstrated in vitro and in vivo activity against these
strains, its presence in these sheep is a logical explanation for these
atypical results. These data emphasize the importance of screening for
phage by enrichment prior to in vivo control/eradication
studies.
Extensive characterization of candidate phages is needed
before any widespread application is implemented. Host selectivity is
key; CEV1 lyses most E. coli O157:H7 strains and a limited
number of commensal E. coli strains. This will create minimal
disturbance to the gut biota, allowing the simultaneous use of
probiotic E. coli to replace O157:H7 within the
gastrointestinal niche and/or to maintain sufficient CEV1 levels to
clear very low levels of E. coli O157:H7.
Our
finding that CEV1 is a close relative of T4 is advantageous; T4-like
phages have a long history of safe application and have been
intensively studied for >50 years
(13,
21,
35,
36). They are exclusively
lytic, and none encode pathogenicity islands, virulence/antibiotic
resistance genes, or integrases. The ability of CEV1 to efficiently
infect E. coli O157:H7 is, however, unusual among T4-like
phages; of the
100 such phages from our collection, only one
infects E. coli O157:H7 at an efficiency of >0.001
(data not shown). Two other reported T4-like O157:H7-infecting phages
(AR1 and PPO1) do not infect lab strains B and K-12, unlike CEV1 (AR1
infects 38/72 ECOR strains, as well as some Proteus,
Shigella, and Salmonella strains; PPO1 infects 8/72
ECOR strains, but with a specificity pattern different from that of
CEV1 (data not shown)
(16).
Previous
researchers have discussed the applications of O157:H7-infecting
phages, but each had some physiological constraint that limited its
application. O'Flynn et al. (2004) used a phage cocktail (PPO1, e4/1c,
and e11/2) to eliminate E. coli O157:H7 from artificially
contaminated meat (28).
This postslaughter approach would initially appear promising in
reducing the postplant E. coli O157:H7 load, but this
application appears impractical (an MOI of
106 and
a temperature of 37°C were used; no phage infection occurred at
lower temperatures). In contrast, our suggested approach with CEV1 is
to treat the live animal and thus reduce E. coli O157:H7
populations before entry into the food chain, allowing the use of phage
in conjunction with other methods to create a multilevel
barrier.
Other preharvest E. coli O157:H7 phage studies
have failed to demonstrate efficacy under real-world conditions. For
example, Kudva et al. reported in 1999 that their O157:H7-infecting
phages effectively killed EDL 932, but only aerobically (MOI,
103); thus, these phage were inappropriate for use
in the anaerobic gut
(20). Bach et al. (2003)
isolated phage DC22, which infected all 23 O157:H7 strains tested in
the lab but showed little or no efficacy in ruminant gut-simulating
chemostats or in lambs
(3). This reinforces the
importance of understanding infection parameters in vitro under
conditions relevant to the ecosystem where the phage will be used.
Tanji et al. (2005) found that a three-phage cocktail worked
effectively in vitro (aerobically and anaerobically) but was unable to
clear mice of E. coli during in vivo studies, again indicating
the complexity of this problem
(38). In our study,
infection of 12900 by CEV1 was productive in TSB aerobically and
anaerobically, as well as in both defined and gut-simulating media
(data not shown). Further, our in vivo trials show a substantial
reduction in intestinal E. coli O157:H7 levels in sheep
treated with a single oral dose of CEV1, suggesting that CEV1 shows
promise as a component in a treatment for the selective reduction of
E. coli O157:H7 levels in food animals.
In summary,
although the United States is considered to have one of the world's
safest food supply systems, people still become ill from bacterially
contaminated food. Our results indicate that phages can reduce
intestinal populations of E. coli O157:H7 and could play an
important role in future preharvest pathogen reduction strategies.
Furthermore, in studies attempting to use intestinal ecological
modification, the potential impact of naturally resident phage must not
be overlooked.
 |
ACKNOWLEDGMENTS
|
|---|
We thank Robert
Droleskey for the electron micrographs; Charles Hernandez, Anna
Castano, and Luki Goldschmidt for assistance with the PFGE experiments;
Travis Steiner, Sarah Perigo, Joe Jardine, Gautam Dutta, Naomi Hoyle,
and Matthew Robison, the undergraduates who helped in many experiments
throughout this project; Burt Guttman for ongoing helpful discussions;
Dan Rice (FDIU strains), Francisco Diez-Gonzalez (strains
86-24 and K-12), and Alison O'Brien (strain 87-23) for kindly providing
E. coli O157:H7 strains; and Yasunori Tanji and
Larry Goodridge for sharing their E. coli O157:H7-targeting
T4-like phages and unpublished data. R.R.R. and R.A.O. thank the
personnel and researchers at the USDA Food and Feed Safety Research
Unit at College Station, Tex., for their hospitality.
This work
was kindly supported by NIH grants 1-R-15 GM63507 and 2-R15 GM063637-02
and by the
USDA/ARS.
 |
FOOTNOTES
|
|---|
* Corresponding
author. Mailing address: Lab II, The Evergreen State College, Olympia,
WA 98505. Phone: (360) 867-4746. Fax: (360) 867-5430. E-mail:
brabbana{at}evergreen.edu. 
 |
REFERENCES
|
|---|
- Adams,
J. C., J. A. Gazaway, M. D. Brailsford,
P. A. Hartman, and N. L. Jacobson.1966
. Isolation of bacteriophages from the bovine rumen.Experientia
22:717-718.[CrossRef]
- Armstrong,
G. L., J. Hollingsworth, and J. G. Morris, Jr.1996
. Emerging foodborne pathogens: Escherichia
coli O157:H7 as a model of entry of a new pathogen into the food
supply of the developed world. Epidemiol. Rev.
18:29-51.[Free Full Text]
- Bach,
S. A., T. A. McAllister, D. M. Veira,
V. P. J. Gannon, and R. A. Holley.2003
. Effect of bacteriophage DC22 on Escherichia
coli O157:H7 in an artificial rumen system (Rusitec) and
inoculated sheep. Anim. Res.
52:89-101.[CrossRef]
- Barrow,
P., M. Lovell, and A. Berchieri. 1998. Use of lytic
bacteriophage for control of experimental Escherichia coli
septicemia and meningitis in chickens and calves. Clin. Diagn.
Lab. Immunol.
5:294-298.
- Besser,
R. E., P. M. Griffin, and L. Slutsker.1999
. Escherichia coli O157:H7 gastroenteritis
and the hemolytic uremic syndrome: an emerging infectious disease.Annu. Rev. Med.
50:355-367.[CrossRef][Medline]
- Bielaszewska,
M., H. Schmidt, A. Liesegang, R. Prager, W. Rabsch, H. Tschape, A.
Cizek, J. Janda, K. Blahova, and H. Karch. 2000.
Cattle can be a reservoir of sorbitol-fermenting Shiga toxin-producing
Escherichia coli O157:H strains and a
source of human diseases. J. Clin. Microbiol.
38:3470-3473.[Abstract/Free Full Text]
- Brabban,
A. D., D. A. Nelson, E. Kutter, T. S.
Edrington, and T. R. Callaway. 2004.
Approaches to controlling Escherichia coli O157:H7, a
food-borne pathogen and an emerging environmental hazard.Environ. Pract.
6:208-229.
- Callaway,
T. R., R. C. Anderson, T. S. Edrington,
K. J. Genovese, K. M. Bischoff, T. L.
Poole, Y. S. Jung, R. B. Harvey, and D.
J. Nisbet. 2004. What are we doing about
Escherichia coli O157:H7 in cattle? J. Anim.
Sci.
82:E93-E99.[Abstract/Free Full Text]
- Callaway,
T. R., R. O. Elder, J. E. Keen,
R. C. Anderson, and D. J. Nisbet.2003
. Forage feeding to reduce preharvest Escherichia
coli populations in cattle: a review. J. Dairy Sci.
86:852-860.[Abstract/Free Full Text]
- Carlson,
K. 2005. Appendix. Working with bacteriophages: common
techniques and methodological approaches, p.437
-494. In E. Kutter and A.
Sulakvelidze (ed.), Bacteriophages: biology and
applications. CRC Press, Boca Raton,
Fla.
- CDC.
2000. Summary of outbreaks of Escherichia coli O157 and other
Shiga toxin-producing E. coli reported to the CDC in 1999.
[Online.]
http://www.cdc.gov/NCIDOD/DBMD/diseaseinfo/files/ecoli_99summary.pdf.
- Chapman,
P. A., C. A. Siddons, D. J. Wright, P.
Norman, J. Fox, and E. Crick. 1993. Cattle as a
possible source of verocytotoxin-producing Escherichia coli
O157 infections in man. Epidemiol. Infect.
111:439-447.[Medline]
- Chibani-Chennoufi,
S., A. Bruttin, M. L. Dillmann, and H. Brussow.2004
. Phage-host interaction: an ecological perspective.J. Bacteriol.
186:3677-3686.[Free Full Text]
- Elder,
R. O., J. E. Keen, G. R. Siragusa,
G. A. Barkocy-Gallagher, M. Koohmaraie, and W. W.
Laegreid. 2000. Correlation of enterohemorrhagic
Escherichia coli O157 prevalence in feces, hides, and
carcasses of beef cattle during processing. Proc. Natl. Acad.
Sci. USA
97:2999-3003.[Abstract/Free Full Text]
- Fischer,
J. R., T. Zhao, M. P. Doyle, M. R.
Goldberg, C. A. Brown, C. T. Sewell, D.
M. Kavanaugh, and C. D. Bauman. 2001.
Experimental and field studies of Escherichia coli O157:H7 in
white-tailed deer. Appl. Environ. Microbiol.
67:1218-1224.[Abstract/Free Full Text]
- Goodridge,
L., A. Gallaccio, and M. W. Griffiths. 2003.
Morphological, host range, and genetic characterization of two
coliphages. Appl. Environ. Microbiol.
69:5364-5371.[Abstract/Free Full Text]
- Grauke,
L. J., I. T. Kudva, J. W. Yoon,
C. W. Hunt, C. J. Williams, and C. J.
Hovde. 2002. Gastrointestinal tract location of
Escherichia coli O157:H7 in ruminants. Appl. Environ.
Microbiol.
68:2269-2277.[Abstract/Free Full Text]
- Greer,
G. G. 2005. Bacteriophage control of
foodborne bacteria. J. Food Prot.
68:1102-1111.[Medline]
- Klieve,
A. V., and T. Bauchop. 1988. Morphological
diversity of ruminal bacteriophages from sheep and cattle. Appl.
Environ. Microbiol.
54:1637-1641.[Abstract/Free Full Text]
- Kudva,
I. T., S. Jelacic, P. I. Tarr, P. Youderian, and
C. J. Hovde. 1999. Biocontrol of
Escherichia coli O157 with O157-specific bacteriophages.Appl. Environ. Microbiol.
65:3767-3773.[Abstract/Free Full Text]
- Kutter,
E., K. Gachechiladze, A. Poglazov, E. Marusich, M. Shneider, P.
Aronsson, A. Napuli, D. Porter, and V. Mesyanzhinov.1995
. Evolution of T4-related phages. Virus
Genes
11:285-297.[CrossRef][Medline]
- Loc
Carrillo, C., R. J. Atterbury, A. El-Shibiny, P. L.
Connerton, E. Dillon, A. Scott, and I. F. Connerton.2005
. Bacteriophage therapy to reduce Campylobacter
jejuni colonization of broiler chickens. Appl. Environ.
Microbiol.
71:6554-6563.[Abstract/Free Full Text]
- Mead,
P. S., and P. M. Griffin. 1998.
Escherichia coli O157: H7. Lancet
352:1207-1212.[CrossRef][Medline]
- Mead,
P. S., L. Slutsker, V. Dietz, L. F. McCaig,
J. S. Bresee, C. Shapiro, P. M. Griffin, and
R. V. Tauxe. 1999. Food-related illness and
death in the United States. Emerg. Infect. Dis.
5:607-625.[Medline]
- Nataro,
J. P., and J. B. Kaper. 1998.
Diarrheagenic Escherichia coli. Clin. Microbiol.
Rev.
11:142-201.[Abstract/Free Full Text]
- Nisbet,
D. J., D. E. Corrier, C. M. Scanlan,
A. G. Hollister, R. C. Beier, and J. R.
DeLoach. 1993. Effect of a defined continuous-flow
derived bacterial culture and dietary lactose on Salmonella
typhimurium colonization in broiler chickens. Avian
Dis.
37:1017-1025.[CrossRef][Medline]
- Ochman,
H., and R. K. Selander. 1984. Standard
reference strains of Escherichia coli from natural
populations. J. Bacteriol.
157:690-693.[Abstract/Free Full Text]
- O'Flynn,
G., R. P. Ross, G. F. Fitzgerald, and A.
Coffey. 2004. Evaluation of a cocktail of three
bacteriophages for biocontrol of Escherichia coli O157:H7.Appl. Environ. Microbiol.
70:3417-3424.[Abstract/Free Full Text]
- Orpin,
C. G., and E. A. Munn. 1973. The
occurrence of bacteriophages in the rumen and their influence on rumen
bacterial populations. Experientia
30:1018-1020.
- Rasmussen,
M. A., W. C. Cray, T. A. Casey, and
S. C. Whipp. 1993. Rumen contents as a
reservoir of enterohemorrhagic Escherichia coli. FEMS
Microbiol. Lett.
114:79-84.[CrossRef][Medline]
- Riley,
L. W., R. S. Remis, S. D. Helgerson,
H. B. McGee, J. G. Wells, B. R. Davis,
R. J. Hebert, E. S. Olcott, L. M.
Johnson, N. T. Hargrett, P. A. Blake, and
M. L. Cohen. 1983. Hemorrhagic colitis
associated with a rare Escherichia coli serotype.N. Engl. J. Med.
308:681-685.[Abstract]
- Smith,
H. W., and M. B. Huggins. 1983.
Effectiveness of phages in treating experimental Escherichia
coli diarrhoea in calves, piglets and lambs. J.
Gen. Microbiol.
129:2659-2675.[Medline]
- Smith,
H. W., M. B. Huggins, and K. M. Shaw.1987
. The control of experimental Escherichia
coli diarrhoea in calves by means of bacteriophages.J. Gen. Microbiol.
133:1111-1126.[Medline]
- Smith,
H. W., M. B. Huggins, and K. M. Shaw.1987
. Factors influencing the survival and multiplication
of bacteriophages in calves and in their environment.J. Gen. Microbiol.
133:1127-1135.[Medline]
- Sulakvelidze,
A., and P. Barrow. 2005. Phage therapy in animals and
agribusiness, p. 335-380. In
E. Kutter and A. Sulakvelidze (ed.), Bacteriophages: biology and
applications. CRC Press, Boca Raton,
Fla.
- Sulakvelidze,
A., and E. Kutter. 2005. Bacteriophage therapy in
humans, p. 381-436. In E.
Kutter and A. Sulakvelidze (ed.), Bacteriophages: biology and
applications. CRC Press, Boca Raton,
Fla.
- Swain,
R. A., J. V. Nolan, and A. V. Klieve.1996
. Natural variability and diurnal fluctuations within
the bacteriophage population of the rumen. Appl. Environ.
Microbiol.
62:994-997.[Abstract]
- Tanji,
Y., T. Shimada, H. Fukudomi, K. Miyanaga, Y. Nakai, and H. Unno.2005
. Therapeutic use of phage cocktail for controlling
Escherichia coli O157:H7 in gastrointestinal tract of mice.J. Biosci. Bioeng.
100:280-287.[CrossRef][Medline]
- Tanji,
Y., T. Shimada, M. Yoichi, K. Miyanaga, K. Hori, and H. Unno.2004
. Toward rational control of Escherichia coli
O157:H7 by a phage cocktail. Appl. Microbiol.
Biotechnol.
64:270-274.[CrossRef][Medline]
- Tetart,
F., C. Desplats, M. Kutateladze, C. Monod, H.-W. Ackermann, and
H. M. Krisch. 2001. Phylogeny of the major
head and tail genes of the wide-ranging T4-type bacteriophages.J. Bacteriol.
183:358-366.[Abstract/Free Full Text]
Applied and Environmental Microbiology, September 2006, p. 6405-6410, Vol. 72, No. 9
0099-2240/06/$08.00+0 doi:10.1128/AEM.03011-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.